Opportunity Information: Apply for CDC RFA PS09 9040401SUPP13
Apply for CDC RFA PS09 9040401SUPP13
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "TECHNICAL ASSISTANCE AND SUPPORT OF HIV PREVENTION, CARE TREATMENT PROGRAMS AND OTHER INFECTIOUS DISEASES THAT IMPACT HIV INFECTED PATIENTS IN SUPPORT OF THE PRESIDENTS EMERGENCY PLAN FOR AIDS RELIEF" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.067 Global AIDS.
- This funding opportunity was created on Oct 10, 2012 and posted on Oct 10, 2012.
- Applicants must submit their applications by Nov 13, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $350,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $635,768.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- The supplemental award should be awarded as a single source award because the grantees is immediately able to implement the activities because this is the only grantee serving the affected region. The grantee has the expertise, experience, and technical capability to complete the activities under the award.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This funding opportunity is a CDC discretionary cooperative agreement under PEPFAR focused on providing urgent technical assistance and program support for HIV prevention, care, and treatment services in South Sudan, along with support for other infectious diseases that affect people living with HIV. It was posted on October 10, 2012 (CDC RFA PS09-9040401SUPP13; CFDA 93.067 Global AIDS) and was designed to stabilize and restart critical services after a major financing disruption that left patients and clinics without the resources needed to continue basic HIV care.
The core problem driving the award is a sudden collapse in program continuity following the end of the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) Round 4 grant, which expired in November 2011. Once that funding ended, South Sudan's national HIV program was unable to secure replacement resources in time. The description emphasizes two immediate consequences: first, people who needed antiretroviral therapy (ART) after late 2012 were unable to access it, and second, health facilities that had previously provided HIV testing stopped offering testing because they could not procure test kits. In practical terms, this meant treatment initiation and potentially even ongoing treatment were at risk, and the pipeline for identifying new patients and linking them to care was breaking down at the same time.
The Government of South Sudan attempted to fill the gap by approving approximately $12 million in January 2012 to continue the HIV activities that had been financed through the GFATM Round 4 grant. However, the country experienced a major and unexpected shock to government revenues when oil income was disrupted; oil reportedly accounted for about 98% of government income, and the lack of a reliable export route prevented the government from allocating the approved funds. The grant opportunity frames CDC/PEPFAR support as an emergency backstop meant to keep essential HIV services functioning when domestic financing could not be executed.
The award structure is notable for being a single expected award and characterized as a single-source supplemental award. The eligibility language indicates the funding was intended to go to a specific existing grantee because that organization was already operating in the affected region and could implement activities immediately. This approach reflects the urgency of the situation: rather than running a broader competition that could delay implementation, CDC planned to rely on an established partner with the technical capacity, experience, and operational footprint needed to rapidly restore services such as ART access and HIV testing.
Financially, the opportunity lists an estimated total funding figure of $350,000,000 for the broader context of the program while specifying an award ceiling and floor of $635,768 for this particular action, indicating a fixed-size award for the supplement described in the notice. There was no cost-sharing or matching requirement. The application window ran to a closing date of November 13, 2012, and the listing was later archived on December 13, 2012.
Overall, the opportunity is best understood as a targeted, time-sensitive CDC/PEPFAR intervention to prevent a prolonged interruption of HIV services in South Sudan after the end of Global Fund support and the failure of anticipated domestic bridge funding. The practical intent was to ensure continuity of HIV treatment and testing capacity, protect patient outcomes, and preserve the basic infrastructure of prevention and care programs during a period of national fiscal instability tied to oil revenue disruptions.
Frequently Asked Questions (FAQs)
What is this funding opportunity?
This opportunity is a CDC discretionary cooperative agreement under PEPFAR. It is focused on providing urgent technical assistance and program support for HIV prevention, care, and treatment services in South Sudan, with additional support for other infectious diseases that affect people living with HIV.
Which agencies and programs are associated with the award?
The notice describes the award as a CDC cooperative agreement under PEPFAR. It is listed under CFDA 93.067 (Global AIDS) and references CDC RFA PS09-9040401SUPP13.
When was the opportunity posted and when did it close?
It was posted on October 10, 2012. The closing date for applications was November 13, 2012.
Is this opportunity still active?
No. The listing was later archived on December 13, 2012.
What situation triggered this emergency funding?
The award was designed to stabilize and restart critical HIV services after a major financing disruption. The disruption followed the end of the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) Round 4 grant, which expired in November 2011, and the national HIV program could not secure replacement funding in time.
What were the immediate service impacts described in the notice?
The description highlights two urgent consequences: (1) people who needed antiretroviral therapy (ART) after late 2012 were unable to access it, and (2) health facilities that previously provided HIV testing stopped offering testing because they could not procure HIV test kits.
How did the funding disruption affect both treatment and new patient identification?
The notice indicates that treatment initiation (and potentially continuity of care) was at risk at the same time that HIV testing capacity was collapsing. That combination threatened the ability to identify new patients and link them to care while also jeopardizing access to ART.
Did the Government of South Sudan attempt to bridge the gap?
Yes. The Government of South Sudan approved approximately $12 million in January 2012 to continue HIV activities that had been financed under GFATM Round 4.
Why was the approved domestic funding not implemented as planned?
The notice attributes the failure to execute the approved funds to a major disruption in oil income. Oil reportedly accounted for about 98% of government income, and the lack of a reliable export route prevented the government from allocating the approved funds.
What is the role of CDC/PEPFAR funding in this context?
The opportunity frames CDC/PEPFAR support as an emergency backstop to keep essential HIV services functioning when domestic bridge financing could not be executed.
What geographic area is the funding meant to support?
The activities described are focused on South Sudan, particularly restoring and stabilizing HIV prevention, care, and treatment services affected by the financing disruption.
What types of activities or services are emphasized?
The notice emphasizes urgent technical assistance and program support to restore continuity of HIV services, including ART access and HIV testing (including procurement-related barriers such as test kits). It also notes support for other infectious diseases affecting people living with HIV.
What is meant by a "cooperative agreement" in this opportunity?
The listing identifies the instrument as a CDC discretionary cooperative agreement. Based on the notice text alone, the key point is that CDC is providing assistance through this mechanism to rapidly support program continuity and urgent implementation needs.
How many awards were expected?
The opportunity anticipated a single award.
Was this a competitive opportunity open to many applicants?
The notice characterizes it as a single-source supplemental award. The eligibility language indicates it was intended for a specific existing grantee already operating in the affected region and able to implement activities immediately, reflecting the urgency and the need to avoid delays.
Why did CDC choose a single-source supplemental approach?
According to the description, the situation required immediate implementation to restore critical services. Using an existing grantee with an operational footprint and relevant experience was presented as the fastest way to restart services such as ART access and HIV testing.
What is the funding amount for this specific action?
For this particular supplemental action, the notice specifies an award floor and ceiling of $635,768, indicating a fixed-size award for the supplement described.
What does the opportunity mean by a larger estimated total funding figure?
The opportunity lists an estimated total funding figure of $350,000,000 in the broader program context, while separately specifying $635,768 as both the ceiling and floor for the specific supplemental award described in the notice.
Was cost sharing or matching required?
No. The notice states there was no cost-sharing or matching requirement.
What outcomes was this funding intended to protect?
The practical intent described is to ensure continuity of HIV treatment and testing capacity, protect patient outcomes, and preserve the basic infrastructure of prevention and care programs during a period of fiscal instability.
What was the underlying economic factor linked to the crisis?
The notice links the fiscal instability to oil revenue disruptions, noting oil reportedly accounted for about 98% of government income and that export-route issues contributed to the inability to allocate the approved domestic funds.
What is the key takeaway about the purpose of this award?
The notice presents this as a targeted, time-sensitive intervention by CDC/PEPFAR to prevent a prolonged interruption of HIV services in South Sudan after Global Fund support ended and anticipated domestic bridge funding could not be executed.
Browse more opportunities from the same agency: Centers for Disease Control and Prevention
Browse more opportunities from the same category: Health
Next opportunity: Hispanic Serving Institutions (HSI) Education Grants Program
Previous opportunity: Digital Humanities Implementation Grants
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA PS09 9040401SUPP13
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA PS09 9040401SUPP13) also looked into and applied for these:
| Funding Opportunity |
|---|
| Presidents Malaria Initiative Apply for USAID GUINEA RFA 675 13 000001 Funding Number: USAID GUINEA RFA 675 13 000001 Agency: Senegal USAID Dakar Category: Health Funding Amount: $18,428,129 |
| Interdisciplinary Approach to Identification and Validation of Novel Therapeutic Targets for Alzheimers Disease (R01) Apply for RFA AG 13 013 Funding Number: RFA AG 13 013 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Alzheimers Disease Prevention Trials (R01) Apply for RFA AG 13 015 Funding Number: RFA AG 13 015 Agency: National Institutes of Health Category: Health Funding Amount: $4,500,000 |
| Alzheimers Disease Phase I Clinical Trials (R01) Apply for RFA AG 13 016 Funding Number: RFA AG 13 016 Agency: National Institutes of Health Category: Health Funding Amount: $800,000 |
| Shared Instrumentation Grant Program (S10) Apply for PAR 13 008 Funding Number: PAR 13 008 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Dynamics of Host Associated Microbial Communities (R01) Apply for RFA GM 14 001 Funding Number: RFA GM 14 001 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Secondary Dataset Analyses in Heart, Lung, and Blood Diseases and Sleep Disorders (R21) Apply for PAR 13 009 Funding Number: PAR 13 009 Agency: National Institutes of Health Category: Health Funding Amount: $75,000 |
| Mentored Research Scientist Development Award in Metabolomics (K01) Apply for RFA RM 12 025 Funding Number: RFA RM 12 025 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Health System Strengthening Project Apply for APS 391 13 000001 Funding Number: APS 391 13 000001 Agency: Pakistan USAID Islamabad Category: Health Funding Amount: $21,900,000 |
| Limited Competition Brain Tissue Resource Center for Alcohol Research (R28) Apply for PAR 13 011 Funding Number: PAR 13 011 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Initiative to Maximize Research Education in Genomics Courses (R25) Apply for PAR 13 012 Funding Number: PAR 13 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Agir pour la Planification Familiale AGIR PF Apply for RFA 624 13 000002 Funding Number: RFA 624 13 000002 Agency: Ghana USAID Accra Category: Health Funding Amount: $29,000,000 |
| Alzheimers Disease Therapeutics Program (U01) Apply for RFA AG 13 014 Funding Number: RFA AG 13 014 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Epigenomics of Virus Associated Oral Diseases (R21) Apply for RFA DE 13 003 Funding Number: RFA DE 13 003 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Epigenomics of Virus Associated Oral Diseases (R01) Apply for RFA DE 13 002 Funding Number: RFA DE 13 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Collaborative Network for Clinical Research on Immune Tolerance (UM1) Apply for RFA AI 12 043 Funding Number: RFA AI 12 043 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Tuberculosis Research Units (U19) Apply for RFA AI 12 045 Funding Number: RFA AI 12 045 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| AHRQ Conference Grant Program (R13) Apply for PA 13 017 Funding Number: PA 13 017 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Limited Competition Collaborative Partnership to Advance Global Biomedical Research Programs (U01) Apply for RFA AI 12 055 Funding Number: RFA AI 12 055 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Age Related Changes in Osteoimmunology (R01) Apply for RFA AG 13 017 Funding Number: RFA AG 13 017 Agency: National Institutes of Health Category: Health Funding Amount: $125,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants

Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA PS09 9040401SUPP13", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.
